Wow! Synergy of apabetalone with SGLT2 inhibitors on renal function and glucose control.....in addition to the MACE data!!!
They don't indicate the magnitude of the eGFR or HbA1c effects, which would be helpful to put this in perspective. While the p<0.001 for the HbA1c is a strong p-value, the p=0.05 for eGFR change is not a very strong p-value. They also don't indicate whether this eGFR change was in the CKD patients that had baseline eGFR below 60 or in the non-CKD patients with baseline eGFR above 60. Still....this is amazing news!
BDAZ
